GlassScriptPhysician profile
Jorge M Abdallah
NPI 1255349361
$1,373.50
in general payments reported to CMS, 2019-2025
13 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $32.42 · 2022: $100 · 2023: $808 · 2024: $149 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,077.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $472.14 | 2023-2025 | Reblozyl, Opdivo |
| Gt Medical Technologies, INC | $191.90 | 2023 | Gammatile |
| Dova Pharmaceuticals | $125.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2024 | Imfinzi |
| Adc Therapeutics America, INC. | $123.37 | 2023 | |
| Janssen Biotech, INC. | $123.37 | 2023 | Tecvayli |
| Kite Pharma, INC. | $100.00 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $27.73 | 2019-2020 | |
| Abbott Laboratories | $23.92 | 2024 | Eterna |
| Merck Sharp & Dohme LLC | $18.25 | 2020 | |
| Genzyme Corporation | $17.55 | 2023 | |
| Exelixis INC. | $12.99 | 2019 | |
| Seagen INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Abdallah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.